Sign in
WithdrawnPhase 1/2

Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS

Key facts

Who runs it
Stem Cell Medicine Ltd.
Where
Israel1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
1 Feb 2024
Ended
1 Feb 2025
Type of study
Interventional, 2 groups
Treatments tested
  • SCM-010
Record updated
18 April 2024
Why it stopped
Due to sponsor decision

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 36 criteriaShow less

Who can take part

  • Male or female subjects (18-60 years of age) diagnosed with SPMS
  • SPMS defined as relapsing-remitting disease followed by progression of disability independent of or not explained by multiple sclerosis (MS) relapses for at least 2 years
  • Subjects should be ambulatory with an EDSS score of 3-6.5 (inclusive) at screening and baseline visits
  • Subjects should be able to go through a lipoaspiration procedure, evaluated by the study's plastic surgeon
  • Women capable of child bearing must have a negative urine pregnancy test at screening and baseline visits
  • Subjects must use an adequate contraceptive method throughout the study
  • Coagulation tests including INR, PTT and prothrombin time (PT) within normal range
  • Subjects must be willing and able to comply with the protocol requirements for the duration of the study
  • Ability to provide written informed consent

Who cannot take part

  • Clinical relapse within 3 months prior to study entry
  • Previous cell therapy treatment
  • Previous total body irradiation or total lymphoid irradiation
  • Previous use of natalizumab or any anti-B cell agent within 6 months prior to screening
  • Previous use of immunosuppressant including Mitoxantrone, Alemtuzumab, Cladribine or any other cytotoxic agent
  • Previous use of Teriflunomide within 12 months if no accelerated elimination procedure was used
  • Previous treatment with immunomodulators (including IFNβ 1a and 1b, and IV Immunoglobulin (IVIG) or Glatiramer Acetate (GA) within 2 months prior to screening
  • Treatment with any kind of steroids or ACTH during the last 30 days prior to screening
  • Subjects with clotting disorders or receiving treatment with anticoagulants
  • Known or suspected drug or alcohol abuse
  • Participation in any investigational drug study within 6 months prior to screening
  • Any chronic central nervous system (CNS) disease other than SPMS
  • Subjects diagnosed with any systemic autoimmune disease
  • Tested positive for HIV, hepatitis (HBV and HCV)
  • Known as positive for VDRL and/or tuberculosis
  • Active malignant disease of any kind. However, a patient, who has had a malignant disease in the past, was treated and is currently disease - free for at least 7 years, may be considered eligible. In this case the sponsor medical expert approval is required
  • A known history of hypersensitivity to one of following: Vancomycin, Cephalosporin, Cephamycin or beta-lactam antibacterial agent (penicillins, monobactams, carbapenems)
  • A known history of sensitivity to Gadolinium
  • Severe anemia (hemoglobin < 10 g/dL)
  • Abnormal renal function (serum creatinine more than 1.5xULN or creatinine clearance <30 ml/min)
  • Previous use of Fingolimod or Dimethyl Fumarate within 2 months prior to screening. Subjects who were treated with any of these medications will be excluded if they do not have a lymphocyte count within normal range at screening
  • Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Principle Investigator, makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study
  • Relapsing remitting multiple sclerosis (RRMS) or primary progressive multiple sclerosis (PPMS) as defined by the revised McDonald criteria
  • Contraindications or inability to undergo lumbar puncture (LP) procedure and or intrathecal administration
  • Inability to successfully undergo MRI scanning
  • Subjects with BMI < 20
  • Pregnant or breast-feeding women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Prospective, single center, open label, phase I/IIa escalating dose study. To evaluate the safety and efficacy of escalating doses of SCM-010 in subjects with SPMS.

The 2 groups in the trial

  • group 1: low doseTreatment being tested

    One intrathecal (IT) administration of SCM-010 at baseline visit

    Treatment: SCM-010

  • group 2: high doseTreatment being tested

    One intrathecal (IT) administration of SCM-010 at baseline visit

    Treatment: SCM-010

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Single Center, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety and Efficacy of an Intrathecal Administration of SCM-010 in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
Record updated
18 April 2024